INNOVATION LEADER

Biopharmaceuticals

Developing advanced biologic therapies to treat rare diseases and cancer through cutting-edge drug discovery and personalized medicine

Drug DiscoveryBiologicsCell TherapyGene Therapy
50+
Research Projects
Active development programs
15
Approved Products
Market-ready therapies
25
Clinical Trials
Ongoing studies
85%
Success Rate
Clinical development

Therapeutic Focus Areas

Oncology

Developing immunotherapy and targeted therapies for difficult-to-treat cancers with high success rates

Key Features:

  • Immunotherapy treatments
  • Targeted therapy approaches
  • CAR-T cell therapy
  • Precision medicine

Applications:

  • Solid tumors
  • Hematologic malignancies
  • Rare cancers
  • Metastatic disease

Rare Diseases

Research and development of therapies for rare diseases, bringing hope to patients with no treatment options

Key Features:

  • Gene therapy solutions
  • Enzyme replacement therapy
  • Orphan drug development
  • Personalized treatments

Applications:

  • Genetic disorders
  • Metabolic diseases
  • Neurological conditions
  • Muscular dystrophies

Autoimmune Diseases

Developing biologic therapies to treat autoimmune diseases like rheumatoid arthritis and lupus

Key Features:

  • Monoclonal antibodies
  • Biologic DMARDs
  • Targeted therapy
  • Immune modulation

Applications:

  • Rheumatoid arthritis
  • Systemic lupus erythematosus
  • Multiple sclerosis
  • Inflammatory bowel disease

Drug Development Pipeline

Phase III

Drugs in Phase III clinical trials with potential for commercialization within 2-3 years

5 Compounds2025-2026High Potential

Phase II

Drugs in Phase II clinical trials with promising initial efficacy data

8 Compounds2026-2027Promising Data

Phase I

New drugs in Phase I clinical trials with breakthrough potential in treatment

12 Compounds2027-2028Breakthrough

Research Achievements

25
Approved Drugs
85%
Success Rate
200+
Patents Filed

Manufacturing Excellence

SO

Biologics Plant Seoul

Seoul, South Korea

Biopharmaceutical manufacturing facility in Seoul with 50,000L capacity, producing monoclonal antibodies

Capacity:50,000L
Timeline:2024

Technologies:

Monoclonal AntibodiesBiologicsQuality Control

Key Results:

  • FDA approved facility
  • ISO 14001 certified
  • Real-time monitoring systems
SW

Cell Therapy Center Basel

Basel, Switzerland

Cell therapy manufacturing center in Basel with advanced CAR-T cell therapy technology

Capacity:CAR-T
Timeline:2025

Technologies:

CAR-T TherapyCell ProcessingCryopreservation

Key Results:

  • GMP certified operations
  • Automated cell processing
  • Quality assurance systems
US

Gene Therapy Facility Boston

Boston, USA

Gene therapy manufacturing facility in Boston with viral vector and gene editing technology

Capacity:Gene Therapy
Timeline:2026

Technologies:

Viral VectorsGene EditingCRISPR Technology

Key Results:

  • FDA breakthrough designation
  • Advanced vector production
  • Precision gene editing

Research & Development

Research Centers

1

AI Drug Discovery

Using artificial intelligence to accelerate drug discovery and predict treatment efficacy

Progress: 80%Timeline: 2024-2026
2

CRISPR Gene Editing

Developing gene therapies using CRISPR technology to treat genetic diseases

Progress: 75%Timeline: 2024-2027
3

Organoid Technology

Using organoid technology to model diseases and test drugs in 3D environments

Progress: 70%Timeline: 2024-2028

Strategic Partnerships

P

Pfizer

Vaccine and biologic therapy development

Joint development of vaccines and biologic therapies

M

Merck

Cancer research and immunotherapy

Cancer research and immunotherapy development

J&J

Johnson & Johnson

Cell and gene therapy development

Cell therapy and gene therapy development

N

Novartis

Rare disease treatments

Rare disease treatment development

The Future of Biopharmaceuticals

Personalized Medicine

Tailored treatments based on individual genetic profiles and disease characteristics

Applications:

  • Genetic profiling
  • Biomarker identification
  • Custom drug formulations
  • Precision dosing
Timeline:2025-2027
Potential Impact:100% personalized treatments

AI-Driven Drug Discovery

Next-generation AI systems that continuously learn and optimize drug development processes

Applications:

  • Machine learning algorithms
  • Predictive modeling
  • Virtual clinical trials
  • Automated compound screening
Timeline:2024-2026
Potential Impact:10x faster drug discovery

Gene Therapy Revolution

Advanced gene editing technologies for curing genetic diseases at the source

Applications:

  • CRISPR gene editing
  • Viral vector delivery
  • Gene replacement therapy
  • Epigenetic modifications
Timeline:2025-2029
Potential Impact:One-time curative treatments

The Future of Biopharmaceuticals

Partner with WMTAN Group to develop advanced biologic therapies that save lives and improve quality of life for patients worldwide.

50+
Research Projects
15
Approved Products
25
Clinical Trials
85%
Success Rate

Biopharmaceuticals Team:portal.wmtan.com/biopharma|Email:biopharma@wmtan.com

CONNECT WITH
WMTAN GROUP

글로벌 리더십과 혁신적인 비전으로 미래를 선도하는 WMTAN Group. 전 세계 50개국에서 펼쳐지는 우리의 여정에 동참하세요.

Global Presence

50+ 국가에서 운영
150+ 계열사 네트워크
1M+ 글로벌 직원

Investor Relations

분기별 실적 발표
연례 주주총회
기업 지배구조 보고서

Business Portal

계열사 포털 사이트
사업 파트너십
글로벌 네트워크

Corporate Governance

기업 윤리 헌장
지속가능경영
사회적 책임 경영

CORE VALUES

Innovation
Cutting-edge technology solutions
Integrity
Ethical business practices
Excellence
Uncompromising quality standards
Sustainability
Responsible growth & impact

QUICK LINKS

STAY UPDATED

Get the latest news, insights, and updates from WMTAN Group delivered to your inbox.

WMTAN GROUP
© 2024 WMTAN Group. All rights reserved worldwide.

WMTAN Group is a global conglomerate committed to sustainable innovation and responsible business practices. Our operations span across energy, technology, healthcare, and financial services sectors worldwide.